Adamax
Quick summary
A modified Semax-type compound listed by the store. Research focus: nootropic peptide research. This page leads with SRP's low-and-slow starting dose.
Overview
A modified Semax-type compound listed by the store. Published primary literature on it is very limited.
Looking for research material? Simple Research Peptides lists Adamax 10 mg Research Compound Vial for laboratory research use.
Mechanism
Published mechanistic data on this compound are limited. See the overview and the linked studies.
Research areas
- nootropic peptide research
Storage & reconstitution
Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.
Recommended starting dose (low and slow)
| Starting dose | Open at 300 mcg once daily (subcutaneous); example uses 0.25 mg. The (nasal) described 100-600 mcg per dose - a different route. |
|---|---|
| Frequency | Reported once or twice daily. |
| Reconstitution | Typically a lyophilized powder dissolved in bacteriostatic water, with the volume chosen to hit the wanted concentration per mL; it gives no worked example. Reconstituted solution kept refrigerated (2-8 °C), not frozen. |
Intranasal use is reported at roughly 100-600 mcg per dose, once or twice daily (some reports go to 900 mcg).
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Some reports go up to 900 mcg per dose (unsupported). |
|---|---|
| Step-up schedules reported | Example steps up every 2 weeks: 300 mcg, then 500 mcg, 750 mcg and 1,000 mcg once daily (weeks 7-8). the same 300-1,000 mcg daily range as 'titrate'. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is Adamax studied for?
In research it is studied for nootropic peptide research. Published mechanistic data on this compound are limited.
How is Adamax given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026